Stockreport

Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF Clinical Activity Observed in 43% of Evaluable Relapsed or Refractory AML and Higher-Risk MDS Patients, Including Improvement in Blood Counts, Reduction [Read more]